middle.news
Microba Accelerates Growth, Eyes Break-Even with $15.7m Revenue in Q2 FY26
9:32am on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
Microba Accelerates Growth, Eyes Break-Even with $15.7m Revenue in Q2 FY26
9:32am on Thursday 29th of January, 2026 AEDT
Key Points
90% year-on-year growth in core test volumes
Annualised run rate surpasses 21,300 tests, targeting >24,000 for break-even
Revenue reaches $15.67 million in Q2 FY26
AI-driven efficiencies and new biomarker features enhance product offering
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MICROBA LIFE SCIENCES (ASX:MAP)
OPEN ARTICLE